Galena Biopharma (GALE) – Press Releases
-
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
-
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
-
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
-
Opthea Appoints US-Based Non-Executive Director
-
Atreca Announces Appointment of Kristine M. Ball to its Board of Directors
-
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance
-
Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel
-
NodThera secures £28 million ($40 million) Series A Financing
-
Galena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse Stock Split Ratio
-
Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote
-
Galena Biopharma Reminds Shareholders to Vote Ahead of Special Meeting on December 15, 2017
-
Galena Biopharma Reports Third Quarter 2017 Financial Results
-
SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA
-
Galena Biopharma Announces Completion of Enrollment in Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
-
Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership
-
State Street Global Advisors Announces Impact of Receiving Settlement Payment
-
Galena Biopharma Reports Second Quarter 2017 Financial Results
-
Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group
-
Galena Biopharma Provides Corporate Update
-
Galena Biopharma Reports First Quarter 2017 Financial Results
-
Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017
-
Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data
-
Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update
-
Galena Biopharma Engages Canaccord Genuity to Advise on Strategic Alternatives
-
Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer
-
Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against Galena BioPharma, Inc.
-
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants
-
Glancy Prongay & Murray LLP Commences Investigation on Behalf of Galena Biopharma, Inc. Investors
-
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants
-
Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants
-
Galena Biopharma Reports Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax™ (nelipepimut-S) Clinical Trials in Combination with Trastuzumab
-
Galena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives
-
Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017
-
Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)
-
Galena Biopharma Announces the Phase 2 Clinical Trial of NeuVax™ (nelipepimut-S) in Ductal Carcinoma in Situ (DCIS) is Open for Enrollment and Screening Patients
-
Galena Biopharma Presented Two Posters at the San Antonio Breast Cancer Symposium
-
Galena Biopharma to Present Two Posters at the San Antonio Breast Cancer Symposium
-
Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the Society for Immunotherapy of Cancer Conference 2016
-
Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update
-
Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer
-
Galena Biopharma Announces Reverse Stock Split
-
Galena Biopharma to Report Third Quarter 2016 Financial Results and Provide a Corporate Update on Wednesday, November 9, 2016
-
Galena Biopharma Presents GALE-301/GALE-302 Phase 1b Data at the American College of Surgeons Clinical Congress 2016
-
Galena Biopharma to Present NeuVax™ (nelipepimut-S) plus Trastuzumab Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
-
Galena Biopharma to Present NeuVax™ (nelipepimut-S) Interim Safety Data at the European Society for Medical Oncology (ESMO) 2016 Congress
-
Galena Biopharma Presents GALE-301 Folate Binding Protein Expression Data at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
-
Galena Biopharma to Present at the Sachs Associates 16th Annual Biotech in Europe Forum
-
Galena Biopharma to Present at the 2016 Aegis Growth Conference
-
Galena Biopharma Presents Preclinical NeuVax™ (nelipepimut-S) Data in Ovarian and Pancreatic Cancer at the Progress in Vaccination Against Cancer (PIVAC) Conference
-
Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
Back to GALE Stock Lookup